Published: 2019-07-23

Study of clinical efficacy, safety and tolerability of low cost branded generic antiepileptic drugs in children and adolescents

Neha Vijay Parekh, Ruth Susan George, Adhiraj Dharmadhikari, Kavita Srivastava, Bijoy Kumar Panda


Background: Generic substitution is preferred to reduce healthcare costs and improve patient adherence. The review of literature showed that physicians all around the world were not comfortable in prescribing generic medications due to the lack of evidence on their safety and efficacy.

Methods: A prospective study was conducted over a period of one year in Pune. The patients were categorized on their age and were assessed for the clinical effectiveness data (no. of breakthrough seizures and seizure free days) and safety data (no. of ADR episodes). The mean number of patients controlled and the frequency of adverse events at the 3rd and 6th month were calculated.

Results: Authors assessed 150 newly diagnosed pediatric epileptic patients who received anti-epileptic drug monotherapy for at least 6 months, out of which 46 (30.66%) received Oxcarbazepine and 104 (69.33%) received Sodium Valproate. At the end of 3 months of therapy 140 (93.33%) patients were seizure free and 145 (96.66%) patients were seizure free at the end of  6 months. Adverse effects were observed in 14 (30.43) patients on oxcarbazepine and 26 (25%) patients on sodium valproate. The most common adverse effect was weight gain in 34 (22.66%) patients with both the AEDs.

Conclusions: Seizure control was achieved in majority of the patients. In addition to the seizure control, the frequency of adverse effects was few and tolerable by the patients when prescribed with low cost branded generics.


Antiepileptic drugs, Branded generic, Epilepsy, Oxcarbazepine, Sodium valproate

Full Text:


References (2019). Epilepsies Information Page | National Institute of Neurological Disorders and Stroke. Available at: Accessed 11 Mar 2019.

Shakirullah, Niaz A., Aslam K, Muhammad N. The Prevalence, Incidence and Etiology of Epilepsy. Int J Clin Exp Neurol. 2014 Dec 28;2(2):29-39.

Gilbert T, Ural A, Lopez M. Five Branded Generics Strategies to Master for Global Pharmaceuticals in Emerging Markets. Accenture Life Sciences, Dublin. 2012.

Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs. Drugs. 2010 Mar 1;70(5):605-21.

Virtual Medical Centre (2009). Generic Antiepileptic Drugs and Branded Antiepileptic Drugs. Available at: (Accessed 11 April 2019).

Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epil Behav. 2004 Dec 1;5(6):995-8.

Knoppert D, Reed M, Benavides S, Totton J, Hoff D, Moffett B, et al. Paediatric age categories to be used in differentiating between listing on a model essential medicines list for children. Word Health Organization position paper. 2007;1(5).

Epilepsy Foundation of Greater Chicago. Breakthrough Seizures. Available at: Accessed 19 April 2019.

FDA. Oxcarbazepine. Accessed 29 April 2018.

FDA. Valproic Acid. Available at: Accessed 29 April 2018.

IBM Micromedex TM. (Accessed 24 February 2019).

Yamada M, Welty TE. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. Ann Pharmacother. 2011 Nov 25; 45(11):1406-15.

Shaw SJ, Hartman AL. The controversy over generic antiepileptic drugs. J Pediatr Pharmacol Therap. 2010 Apr;15(2):81-93.

Atif M, Azeem M, Sarwar MR. Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature. SpringerPlus. 2016 Dec 1;5(1):182.

Rahman MM, Alatawi Y, Cheng N, Qian J, Plotkina AV, Peissig PL, et al. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the US Food and Drug Administration Adverse Event Reporting System (FAERS). Epilepsy research. 2017 Sep 1;135:71-8.

National Institute for Health Clinical Excellence (NICE). Epilepsies: Diagnosis and Management. Available at: Accessed 26 February 2019.

Medicines and Healthcare products Regulatory Agency - GOV.UK. 2018 Available at: Accessed 29 April 2018.

Naik N, Gawai A. Efficacy, safety and tolerability of Trioptal®(oxcarbazepine) in children and adolescents with newly diagnosed partial seizures or generalized tonic-clonic seizures: results of a 6 months, prospective, open-label, multicentre, non-comparative, observational post-marketing surveillance study. Ind Med Gazette. 2012;146:324-30.

Belousova ED, Mukhin K, Ermolenko NA, Guzeva VI, Tysiachina MD, Mironov MB, et al. Efficacy and safety of the monotherapy with trileptal (oxcarbazepine) in children and adolescents. Zhurnal Nevrologii i Psikhiatrii Imeni SS Korsakova. 2010;110(5 Pt 1):45-50.

Richens A, Ahmad S. Controlled trial of sodium valproate in severe epilepsy. Br Med J. 1975 Nov 1;4(5991):255-6.